Novel Attenuated Strains of Mycobacterium Tuberculosis
Posted Feb 27 2011 7:00pm
Description of Invention: This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by deleting the gene encoding the alpha-crystallin heat shock protein ("acr gene"). This gene contributes to the virulence of the organism. Since this strain is isogenic with virulent M. tuberculosis but for this deletion, the full complement of antigens remains present and the organism is viable in vitro. The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.
For Licensing Information Please Contact: Admin. Licensing Spec-InfectDis NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: anos@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220
Description of Invention:
This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by deleting the gene encoding the alpha-crystallin heat shock protein ("acr gene"). This gene contributes to the virulence of the organism. Since this strain is isogenic with virulent M. tuberculosis but for this deletion, the full complement of antigens remains present and the organism is viable in vitro. The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.
Inventors:
Clifton E Barry (NIAID)
Patent Status:
HHS, Reference No. E-238-1997/0
PCT, Application No. PCT/US98/14227 filed 09 Jul 1998
HHS, Reference No. E-238-1997/0
Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
For Licensing Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220
Ref No: 421
Updated: 02/2011